Omicap 20Mg

COMPOSITION

Each capsule contains: Omeprazole USP 20 mg (as enteric-coated pellets) 

INDICATIONS

Omeprazole capsules are indicated for: Helicobacter pylori eradication in combination with amoxicillin and clarithromycin: or in combination with amoxicillin and metronidazole: or in combination with clarithromycin and metronidazole. Benign gastric ulceration. Duodenal ulceration. Prevention of relapse in gastric ulcer. Prevention of relapse in duodenal ulcer. NSAlD-associated duodenal ulcer. NSAlD-associated gastric ulcer. NSAlD-associated gastro duodenal erosions. Prophylaxis in patients with a history of NSAlD-associated duodenal ulcer who require continued NSAID treatment. Prophylaxis in patients with a history of NSAlD-associated gastric ulcer who require continued NSAID treatment. Prophylaxis in patients with a history of NSAID-associated gastro duodenal lesions who require continued NSAID treatment. Prophylaxis in patients with a history of NSAlD-associated dyspeptic symptoms who require continued NSAID treatment. Zollinger-Ellison syndrome. Gastro-esophageal reflux disease. Gastro-esophageal reflux disease refractory to other treatment. Acid reflux disease (long-term management). Acid-related dyspepsia. 

CONTRAINDICATIONS

Hypersensitivity to omeprazole, substituted benzimidazoles or to any of the excipients Omeprazole like other proton pump Inhibitors (PPIs) must not be used concomitantly with nelfinavir. 

SIDE EFFECTS/ADVERSE EFFECTS

For all PROTONS PUMP INHIBITORS: Common or very common: Abdominal pain; constipation; diarrhea: flatulence; gastro-intestinal disturbances; headache; nausea; vomiting. Uncommon: Arthralgia; dizziness; dry mouth; fatigue; myalgia: paresthesia; peripheral oedema; pruritus; rash; Sleep disturbances. Rare: Alopecia; anaphylaxis; blood disorders; bronchospasm: confusion: depression; fever; gynecomastia; hallucinations; hepatitis; hypersensitivity reactions; hypomagnesaemia (usually after 1 year of treatment. but sometimes after 3 months of treatment); hyponatremia; interstitial nephritis jaundice, leukocytosis; leucopenia; pancytopenia; photosensitivity; Stevens-Johnson syndrome; stomatitis; sweating; taste disturbance; thrombocytopenia; toxic epidermal necrolysis; visual disturbances. Side-effects, further information: Rebound acid hypersecretion and protracted dyspepsia may occur after stopping prolonged treatment with a proton pump inhibitor. For OMEPRAZOLE: Frequency not known: Agitation; impotence. 

PRECAUTIONS & WARNINGS

For all PROTONS PUMP INHIBITORS: Can increase the risk of fractures (particularly when used at high doses for over a year in the elderly) (in adults); may increase the risk of gastro-intestinal infections (including Clostridium difficile infection): may mask the symptoms of gastric cancer (in adults); patients at risk of osteoporosis. Cautions, further information: Risk of osteoporosis: Patients at risk of osteoporosis should maintain an adequate intake of calcium and vitamin D, and if necessary, receive-other preventative therapy. Gastric cancer: Particular care is required in those presenting with 'alarm features', in such cases gastric malignancy should be ruled out before treatment. Hepatic impairment: Dose adjustments. Not more than 20mg daily should be needed. Patient and carer advice: With oral use: Counseling on administration advised. 

MICRO LABS LIMITED